Biotech

All Articles

Ideaya bags choice on Biocytogen bispecific ADC in $400M bargain

.Ideaya Biosciences is actually wagering $400 million in biobucks that a bispecific antibody-drug co...

Takeda takes $140M reduction on fallen short epilepsy medication, promotes FDA run

.Our company presently know that Takeda is wishing to find a path to the FDA for epilepsy medication...

VBI Vaccines declare personal bankruptcy, seeks asset sale

.Immunology biotech VBI Vaccinations is veering alarmingly near the defining moment, with plannings ...

Celldex anti-cKIT antibody reduce hives in another stage 2 study

.It's not easy to muscle mass in on an area as very competitive as immunology, yet Celldex Therapies...

Boehringer provides to $1.3 B for checkpoint inhibitor biotech

.Boehringer Ingelheim is offering up to $1.3 billion for Nerio Therapies and also a preclinical immu...

Ventyx's last hope for inflamed med ends in Crohn's breakdown

.Ventyx Biosciences' Crohn's illness medicine performed certainly not assist clients accomplish remi...

Cognition's period 2 SHINE information tarnish Alzheimer's prospect

.Knowledge Therapies' phase 2 sparkle test has actually taken some of the gloss off the Alzheimer's ...

BMS axes bispecific months after submitting to run stage 3 test

.Bristol Myers Squibb has actually had a whiplash change of mind on its own BCMA bispecific T-cell e...

Charles Baum consumes Terremoto as CEO

.Charles Baum, M.D., Ph.D., who oversaw Mirati Therapeutics' $ 5.8 billion sale to Bristol Myers Squ...

Asarina to shut after efforts to partner Tourette's medicine fall short

.After connecting to more than 200 companies to partner a Tourette syndrome treatment that revealed ...